stock decline

Portnoy Law Firm launches class action lawsuit against Alight, Inc. for allegedly making false revenue statements. Stock plummeted 56% cumulatively across two separate crashes in 2025-2026.

Boston Scientific faces class action lawsuit after 17% stock decline following $0.45 EPS miss versus $0.48-$0.52 guidance, amid alleged undisclosed Electrophysiology market share losses.

Trip.com stock plummeted 17% after China's antitrust regulator launched investigation into alleged monopolistic practices, sparking class action lawsuit.

Trip.com ($TCOM) plummeted 17% after China's market regulator launched antitrust investigation. Class action lawsuit targets investors with losses exceeding $100,000.

Plug Power faces securities fraud lawsuit alleging DOE loan overstatements. Class period: January-November 2025. Investors can seek lead plaintiff status by April 3, 2026.

Snowflake faces class action lawsuit alleging false statements about product efficiency, with stock down 18% during June 2023-February 2024 period. Lead plaintiff applications due April 2026.

Soleno Therapeutics faces securities fraud lawsuit over alleged safety misstatements in DCCR clinical trial. Stock fell 26% following August short-seller report.

Kirby McInerney LLP filed class action lawsuit against $TCOM for allegedly understating regulatory risks before January 2026 stock plunge.

Soleno Therapeutics faces class action lawsuit over DCCR safety concealment claims, with investors suffering significant losses following critical short-seller report and patient death disclosure.

Inovio Pharmaceuticals faces a securities class action over allegedly false statements regarding manufacturing capabilities and regulatory prospects for INO-3107, following FDA's December 29 accelerated approval rejection.

Securities fraud investigation launched against $ALIT following 18.3% and 38.2% stock declines tied to missed revenue guidance and earnings shortfalls in 2025-2026.

American Airlines dropped 16.91% amid Iran tensions, while Delta fell just 1.32% and United declined 12.33%. Delta faces $400M in fuel costs; American projects 10%+ Q1 revenue growth despite earnings losses.

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant. Stock crashed 50% following misleading investor claims about approval prospects.

BellRing Brands faces securities fraud class action for failing to disclose inventory issues. Stock plummeted 52% after May and August 2025 negative announcements.

Apollo Global Management faces securities fraud lawsuit alleging executives hid communications with Jeffrey Epstein. Stock declined 16% during relevant period; investor deadline May 1, 2026.

Ultragenyx faces securities lawsuit after setrusumab Phase 3 trial failure. Stock fell 42%. Investors must apply for class action lead plaintiff status by April 6, 2026.

Saxena White filed expanded securities class action against Kyndryl for allegedly misleading investors on free cash flow metrics across an 18-month period amid governance failures.

Kyndryl faces securities fraud lawsuit after revealing internal control weaknesses and executive departures. Stock plunged 55% to $10.59; investor deadline April 13, 2026.

Driven Brands faces securities lawsuit after disclosing material financial statement errors. Stock fell 40% following February 2026 announcement; investors have until May 8 to file.

Trip.com faces securities fraud lawsuit after China's antitrust probe; stock plunged 19.4% with investors losing $12.90 per share initially.